multiple myeloma
Item
all patients must have a confirmed malignancy which can be classified as locally advanced or distant metastatic disease and must have either 1) failed on standard therapy or 2) have disease for which in the opinion of the investigator, no adequate standard +therapy exists.
boolean
C0026764 (UMLS CUI [1])
age, pregnany, contraception
Item
patients must be 18 years of age or older. women of childbearing potential must have a negative pregnancy test and fertile women and men must use a medically acceptable means of birth control while on study and for 6 months thereafter.
boolean
C0001779 (UMLS CUI [1])
C0032961 (UMLS CUI [2])
C0700589 (UMLS CUI [3])
informed consent
Item
patients must sign an informed consent to participate in this study.
boolean
C0021430 (UMLS CUI [1])
swog performance status
Item
swog performance status 0-3, unless related to cancer pain.
boolean
C1518965 (UMLS CUI [1])
pregnancy test
Item
before starting treatment, women of childbearing potential should have a negative pregnancy test performed within 24 hours prior to beginning therapy.
boolean
C0032961 (UMLS CUI [1])
post-menopausal or hysterectomy
Item
pregnancy testing is not required for 1) women who have been post-menopausal for at least 2 years with no menses, 2) women who have had a hysterectomy.
boolean
C0232970 (UMLS CUI [1])
C0020699 (UMLS CUI [2])
hematologic, renal and hepatic function
Item
patients must have adequate hematologic function as demonstrated by total white blood count > or = 2000/mm3, adequate renal function as demonstrated by serum creatinine < or = 3.0 mg/dl, and adequate hepatic function as demonstrated by bilirubin < or =1.5 mg/dl and transaminases < or =4 x uln.
boolean
C0023508 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
C1278039 (UMLS CUI [3])
C0002594 (UMLS CUI [4])
patients must not be eligible for any uams participating clinical trial of higher priority.
Item
patients must not be eligible for any uams participating clinical trial of higher priority.
boolean
C2348568 (UMLS CUI [1])